Read by QxMD icon Read


Keith M Sigel, Kimberly Stone, Juan P Wisnivesky, Lesley S Park, Chung Yin Kong, Michael J Silverberg, Sheldon Brown, Matthew Goetz, Maria C Rodriguez-Barradas, Cynthia Gibert, Fatma Shebl, Roger Bedimo, Roxanne Wadia, Joseph King, Kristina Crothers
OBJECTIVE: Lung cancer is the leading cause of cancer death in people living with HIV (PWH). Surgical resection is a key component of potentially curative treatment regimens for early-stage lung cancers, but its safety is unclear in the setting of HIV. From a national cohort, we assessed potential differences in the risk of major lung cancer surgery complications by HIV status. DESIGN: We linked clinical and cancer data from the Veterans Aging Cohort Study (VACS) and Veterans Affairs Corporate Data Warehouse to outcomes from the Veterans Affairs Surgical Quality Improvement Program (VASQIP) and identified 8371 patients (137 PWH, 8234 uninfected) who underwent lung cancer surgeries between 2000 and 2016...
March 15, 2019: AIDS
Maarten Reitsema, Linda Steffers, Maartje Visser, Janneke Heijne, Albert Jan Van Hoek, Maarten Schim Van Der Loeff, Ard Van Sighem, Birgit Van Benthem, Jacco Wallinga, Maria Xiridou, Marie-Josee Mangen
OBJECTIVES: To assess the cost-effectiveness of increased consistent HIV testing among men who have sex with men (MSM) in the Netherlands. METHODS: Among MSM testing at STI clinics in the Netherlands in 2014-2015, approximately 20% tested consistently every six months. We examined four scenarios with increased percentage of MSM testing every six months: a small and a moderate increase among all MSM; a small and a moderate increase only among MSM with ≥10 partners in the preceding six months...
March 15, 2019: AIDS
Qing-Hai Li, Bing Shao, Jin Li, Jia-Ye Wang, Bo Song, Yuan-Long Lin, Qing-Qing Huo, Si-Yu Liu, Fu-Xiang Wang, Shu-Lin Liu
OBJECTIVE: This study aimed to understand epidemiological feature and critical factors associated with pathogenesis of CRF01_AE strains in Northeast China. DESIGN: Compared analysis was made between CRF01_AE and non-CRF01_AE samples to understand the pathogenicity features of CRF01_AE. Further analyses between CRF01_AE samples with high or low CD4 cell counts and between samples with different coreceptor usages were done to explore the possible factors correlating to the pathogenesis of CRF01_AE viruses...
March 13, 2019: AIDS
Amélie Cattin, Tomas Raul Wiche Salinas, Annie Gosselin, Delphine Planas, Barbara Shacklett, Eric A Cohen, Maged P Ghali, Jean-Pierre Routy, Petronela Ancuta
OBJECTIVE: To explore the contribution of blood and colon myeloid cells to HIV persistence during antiretroviral therapy (ART). DESIGN: Leukapheresis were collected from HIV-infected individuals with undetectable plasma viral load during ART (HIV + ART; n = 15) and viremics untreated (HIV + ; n = 6). Rectal sigmoid biopsies were collected from n = 8 HIV+ART. METHODS: Myeloid cells (total monocytes (Mo), CD16/CD16 Mo, CD1c dendritic cells (DC)) and CD4 T-cells were isolated by MACS and/or FACS from peripheral blood...
March 11, 2019: AIDS
Mathieu F Chevalier, Nupur Bhatnagar, Céline Didier, Moises Lopez-Gonzalez, Juliette Pavie, Diane Bollens, Claudine Duvivier, Lio Collias, Corinne Jung, Daniel Scott-Algara, Pierre-Marie Girard, Laurence Weiss
OBJECTIVES: HIV controllers (HIC) are rare HIV-infected individuals able to maintain undetectable viremia in the absence of antiretroviral treatment. While HIV-specific cytotoxic T cells have been well deciphered in HIC, γδ T lymphocytes remain largely uncharacterized. The aim of this study was to analyze phenotypic and functional characteristics of γδ T cells and their relationship with immune activation, which remain abnormally elevated and associated with comorbidities in HIC. METHODS: PBMC were isolated from 16 HIC, 16 patients with untreated chronic HIV infection (UT-CHI) and 20 healthy donors (HD)...
March 11, 2019: AIDS
Thibaut Davy-Mendez, Sonia Napravnik, Oksana Zakharova, David A Wohl, Claire E Farel, Joseph J Eron
OBJECTIVE: Characterize virologic and immunologic outcomes of INSTI-based antiretroviral therapy (ART) in experienced patients with and without virologic failure. DESIGN: Prospective clinical cohort. METHODS: ART-experienced, INSTI-naïve participants in the University of North Carolina Center for AIDS Research HIV Clinical Cohort (UCHCC) initiating an INSTI-containing regimen 2007-2016 were followed from INSTI initiation (baseline) to the earliest of: outcome of interest, loss to follow-up (LTFU, one year without clinical visit), or death...
March 11, 2019: AIDS
Anna M Leddy, Janet M Turan, Mallory O Johnson, Torsten B Neilands, Mirjam-Colette Kempf, Deborah Konkle-Parker, Gina Wingood, Phyllis C Tien, Tracey E Wilson, Carmen H Logie, Sheri D Weiser, Bulent Turan
OBJECTIVE: To examine whether experienced poverty stigma is associated with worse HIV care and treatment outcomes. DESIGN: We analyzed cross-sectional data from 433 women living with HIV enrolled in the Women's Adherence and Visit Engagement (WAVE) sub-study of the Women's Interagency HIV Study (WIHS). METHODS: Exposure was experienced poverty stigma, measured using the Perceived Stigma of Poverty Scale. Outcomes were viral suppression, CD4 cell count ≥350 cells/mm, and attending all HIV care visits in the past six months...
March 11, 2019: AIDS
Christopher D Pilcher, Travis C Porco, Shelley N Facente, Eduard Grebe, Kevin P Delaney, Silvina Masciotra, Reshma Kassanjee, Michael P Busch, Gary Murphy, S Michele Owen, Alex Welte
OBJECTIVE: To determine the precision of new and established methods for estimating duration of HIV infection. DESIGN: A retrospective analysis of HIV testing results from serial samples in commercially-available panels, taking advantage of extensive testing previously conducted on 53 seroconverters. METHODS: We initially investigated four methods for estimating infection timing: 1) "Fiebig stages" based on test results from a single specimen; 2) an updated "4 gen" method similar to Fiebig stages but using antigen/antibody tests in place of the p24 antigen test; 3) modeling of "viral ramp-up" dynamics using quantitative HIV-1 viral load data from antibody-negative specimens; and 4) using detailed clinical testing history to define a plausible interval and best estimate of infection time...
March 11, 2019: AIDS
Rowan Saloner, Robert K Heaton, Laura M Campbell, Anna Chen, Donald Franklin, Ronald J Ellis, Ann C Collier, Christina Marra, David B Clifford, Benjamin Gelman, Ned Sacktor, Susan Morgello, J Allen Mccutchan, Scott Letendre, Igor Grant, Christine Fennema-Notestine
OBJECTIVE: The influence of confounding neurocognitive comorbidities in persons living with HIV (PLWH) on neuroimaging has not been systematically evaluated. We determined associations between comorbidity burden and brain integrity and examined the moderating effect of age on these relationships. DESIGN: Observational, cross-sectional substudy of the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) cohort. METHODS: 288 PLWH (mean age=44...
March 11, 2019: AIDS
Antonella Castagna, Stefano Rusconi, Roberto Gulminetti, Stefano Bonora, Giovanni Mazzola, Maria Eugenia Quiros-Roldan, Giuseppe Vittorio De Socio, Nicoletta Ladisa, Sinibaldo Carosella, Annamaria Cattelan, Simona Di Giambenedetto, Maurizio Mena, Andrea Poli, Laura Galli, Agostino Riva
: We evaluated efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA > 50 copies/ml.During a median follow-up of 62 (42-97) weeks, 2 VFs (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of VF was 0.8% (95% CI = 0.2%-5.6%).Switch to DTG + uATV may represent a boosting and RTIs sparing option in subjects with long exposure to ART and risk of cardiovascular disease.
March 11, 2019: AIDS
Ryan Sanford, Jeremy Strain, Mahsa Dadar, Josefina Maranzano, Alexandre Bonnet, Nancy E Mayo, Susan C Scott, Lesley K Fellows, Beau M Ances, D Louis Collins
OBJECTIVE: Investigate whether cerebral small vessel disease (CSVD) is more common in virologically-suppressed HIV-positive participants compared to HIV-negative controls and examine the potential synergistic effects of HIV and CSVD on brain structure and cognition. DESIGN: Cross-sectional analysis of 119 treated, virologically-suppressed HIV-positive and 55 HIV-negative participants. 46 HIV-positive and 30 HIV-negative participants had follow-up two-years later...
March 11, 2019: AIDS
Bo L Hønge, Mikkel S Petersen, Sanne Jespersen, Candida Medina, David D S Té, Bertram Kjerulff, Thomas Engell-Sørensen, Tina Madsen, Alex L Laursen, Christian Wejse, Henrik Krarup, Bjarne K Møller, Christian Erikstrup
BACKGROUND: For unknown reasons, HIV-2 is less pathogenic than HIV-1, and HIV-2 induced immunodeficiency may be different from that caused by HIV-1. Previous immunological studies have hinted at possible shifts in both T and B-cell subsets, which we aimed to characterize further. METHODS: From an HIV clinic in Guinea-Bissau, 63 HIV-2, 83 HIV-1, and 26 HIV negative participants were included. All HIV infected participants were ART naïve. The following cell subsets were analysed by flow cytometry; T cells (maturation and activation), regulatory T cells, and B cells (maturation and activation)...
March 5, 2019: AIDS
Bo L Hønge, Mikkel S Petersen, Sanne Jespersen, Candida Medina, David D S Té, Bertram Kjerulff, Mads M Jensen, Ditte Steiniche, Joakim Esbjörnsson, Alex L Laursen, Christian Wejse, Henrik Krarup, Bjarne K Møller, Christian Erikstrup
BACKGROUND: HIV-2 may slow progression of a subsequently acquired HIV-1 infection through cross-neutralizing antibodies and polyfunctional CD8+ T cells. We hypothesized that HIV-1/2 dually infected patients compared to HIV-1 infected patients had more preserved immune maturation subsets and less immune activation of T and B-cells. METHODS: ART-naïve patients with HIV-1 (n = 83) or HIV-1/2 dual (n = 27) infection were included in this cross-sectional study at an HIV clinic in Guinea-Bissau...
March 5, 2019: AIDS
Anaïs Corma-Gómez, Luis Morano Amado, Francisco Téllez, Antonio Rivero-Juárez, Luis Miguel Real, Juan Carlos Alados, María José Ríos-Villegas, Francisco Jesús Vera-Méndez, Rosario Palacios Muñoz, Paloma Geijo, Juan Macías, Juan A Pineda
OBJECTIVE: To assess the impact of HIV-coinfection on the risk of developing liver related complications in HCV-infected patients with advanced fibrosis treated with direct-acting antivirals (DAA) after sustained virological response (SVR). DESIGN: Prospective cohort study SETTING:: Multicenter SUBJECTS:: Patients from the GEHEP and HEPAVIR cohorts, were selected if they fulfilled the following criteria: 1) Treatment against HCV with all oral DAA combination; 2) SVR achievement, defined as undetectable plasma HCV RNA 12 weeks after the end of therapy; 3) Pre-treatment liver stiffness (LS) equal to or higher than 9...
March 5, 2019: AIDS
Robert J Flick, Katherine R Simon, Rose Nyirenda, Khumbo Namachapa, Mina C Hosseinipour, Alan Schooley, Elijah Kavuta, Joe Theu, Peter N Kazembe, Saeed Ahmed, Maria H Kim
OBJECTIVES: In 2015, Malawi piloted the HIV Diagnostic Assistant (HDA), a cadre of lay health worker focused primarily on HIV testing services. Our objective is to measure the effect of HDA deployment on country-level HIV testing measures. DESIGN: Interrupted time series analysis of routinely collected data to assess immediate change in absolute numbers and longitudinal changes in trends. METHODS: Data from all HDA sites was divided into two periods: pre-deployment (October 2013 to June 2015) and post-deployment (July 2015 to December 2017)...
March 4, 2019: AIDS
Birgitte Stiksrud, Hans C D Aass, Kristina B Lorvik, Thor Ueland, Marius Trøseid, Anne M Dyrhol-Riise
OBJECTIVE: To explore monocyte and dendritic cell (DC) immune responses, and their association with future CD4 gain in treated HIV patients with suboptimal CD4 recovery. DESIGN: A cross-sectional study of HIV-infected, virally suppressed individuals on antiretroviral therapy (ART) for ≥24 months; 41 immunological non-responders (INR) (CD4 < 400 cells/μL) and 26 immunological responders (IR) (CD4 > 600 cells/μL). Ten HIV-infected ART-naive and ten HIV-negative healthy persons served as controls...
February 14, 2019: AIDS
Bart G J Dekkers, Wouter F W Bierman, Daan J Touw, Jan-Willem C Alffenaar
No abstract text is available yet for this article.
February 7, 2019: AIDS
Man K Chan, Ruth Goodall, Ali Judd, Nigel Klein, Elena Chiappini, Thomas Klimkait, Nicole Ngo-Giang-Huong, Paolo Palma, Paolo Rossi, Claire Thorne, Anna Turkova, Paola Zangari, Pieter L Fraaij, Dasja Pajkrt, Laura Marques, Intira J Collins, Diana M Gibb, Maria I Gonzalez-Tome, Maria L Navarro, Jose T Ramos, Antoni Noguera-Julian, Josiane Warszawski, Christoph Königs, Vana Spoulou, Filipa Prata, Tessa Goetghebuer, Luisa Galli, Lars Naver, Carlo Giaquinto, Magdalena Marczynska, Liubov Okhonskaia, Ruslan Malyuta, Alla Volokha, Luminita Ene, Pablo Rojo, Abdel G A Babiker
OBJECTIVE: To identify predictors of faster time to virological suppression among infants starting combination antiretroviral therapy (cART) early in infancy. DESIGN: Cohort study of infants from Europe and Thailand included in studies participating in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC). METHODS: Infants with perinatal HIV starting cART aged <6 months with ≥1 viral load (VL) measurement within 15 months of cART initiation were included...
February 7, 2019: AIDS
Sascha Albrecht, Fabian C Franzeck, Herry Mapesi, Christoph Hatz, Aneth V Kalinjuma, Tracy R Glass, Dorcas Mnzava, Emili Letang, Daniel H Paris, Manuel Battegay, Maja Weisser
OBJECTIVE: Causes of morbidity and mortality of people living with HIV are changing with access to antiretroviral therapy and increased life expectancy. Age-related data on comorbidities and their impact on mortality in sub-Saharan Africa are scarce. DESIGN: This prospective analysis evaluated comorbidities, assessed by means of International Classification of Diseases and Related Health problems 10th revision codes and clinical variables, derived from data collected from the Kilombero & Ulanga antiretroviral cohort of people living with HIV in rural Tanzania...
February 7, 2019: AIDS
Sikhulile Moyo, Simani Gaseitsiwe, Melissa Zahralban-Steele, Dorcas Maruapula, Tapiwa Nkhisang, Baitshepi Mokaleng, Terence Mohammed, Tsotlhe R Ditlhako, Ontlametse T Bareng, Thatayaone P Mokgethi, Erik van Widenfelt, Molly Pretorius-Holme, Madisa O Mine, Elliot Raizes, Etienne Kadima Yankinda, Kathleen E Wirth, Tendani Gaolathe, Joseph M Makhema, Shahin Lockman, Max Essex, Vlad Novitsky
BACKGROUND: Scale-up of antiretroviral therapy (ART) and introduction of treat-all strategy necessitates population-level monitoring of acquired HIV drug resistance (ADR) and pre-treatment drug resistance (PDR) mutations. METHODS: Blood samples were collected from 4,973 HIV-positive individuals residing in 30 communities across Botswana who participated in the Botswana Combination Prevention Project (BCPP) in 2013-2018. HIV sequences were obtained by long-range HIV genotyping...
February 7, 2019: AIDS
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"